Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer

PurposeLiposomal cisplatin was developed to reduce the systemic toxicity of cisplatin, particularly the nephrotoxicity, and it has been used in combination with other agents in pancreatic and head and neck cancers and non-small-cell lung cancer (NSCLC). Our objective was to compare the effectiveness of lipoplatin combined with paclitaxel versus cisplatin with paclitaxel in advanced non-squamous NSCLC.MethodsDuring 2007–2010, 202 patients with non-squamous NSCLC (stage IIIB and IV) were recruited from the two participating institutions and divided into two arms: Arm A was treated with liposomal cisplatin 200 mg/m2 combined with paclitaxel 135 mg/m2 and Arm B with cisplatin 75 mg/m2 in combination with paclitaxel 135 mg/m2, repeated every 2 weeks. The number of cycles administered was 632 (Arm A) and 640 (Arm B), totaling 1,272.ResultsA partial response was achieved by 59.22% of Arm A patients versus 42.42% of Arm B, and the difference was statistically significant (P 0.036). The median survival time in months was 10 for Arm A and 8 for Arm B (P 0.1551). After 18 months, the number of surviving patients was double for Arm A versus Arm B.ConclusionLiposomal cisplatin in combination with paclitaxel produces a statistically significantly higher response rate than cisplatin combined with paclitaxel in non-squamous NSCLC.

[1]  M. Schäfer,et al.  Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  D. Finkelstein,et al.  Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[4]  T. Boulikas,et al.  Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. , 2005, Anticancer research.

[5]  G. Stathopoulos,et al.  Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin. , 1999, Oncology reports.

[6]  A. Ardizzoni,et al.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.

[7]  D. Amadori,et al.  Activity of lipoplatin in tumor and in normal cells in vitro , 2008, Anti-cancer drugs.

[8]  M. al-Sarraf.  Chemotherapeutic management of head and neck cancer , 2004, Cancer and Metastasis Reviews.

[9]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[10]  G. Peters,et al.  Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  K. Kao,et al.  Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer. , 2007, Chang Gung medical journal.

[12]  C. Kosmas,et al.  Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. , 2010, Lung cancer.

[13]  Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study. , 2010, Anticancer research.

[14]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[15]  G. Giaccone.  Twenty-five years of treating advanced NSCLC: what have we achieved? , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  K. Pienta,et al.  Testicular Cancer , 2009, Nature Reviews Disease Primers.

[17]  G. Scagliotti,et al.  Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): P2-328 , 2007 .

[18]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[19]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[20]  F. Tas,et al.  Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer , 2008, Investigational New Drugs.

[21]  H. Humes.  Insights into Ototoxicity , 1999 .

[22]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[23]  T. Boulikas,et al.  Low renal toxicity of lipoplatin compared to cisplatin in animals. , 2004, Anticancer research.

[24]  M. Gore,et al.  Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Humes.  Insights into ototoxicity. Analogies to nephrotoxicity. , 1999, Annals of the New York Academy of Sciences.

[26]  S. Arbuck,et al.  #420 Common toxicity criteria (ctc) version 2.0: highlights and tools , 1999 .

[27]  T. Boulikas,et al.  Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. , 2005, Oncology reports.

[28]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[29]  T. Boulikas,et al.  Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. , 2006, Oncology reports.

[30]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[32]  E. Smit,et al.  Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage III1 N2 non-small-cell lung cancer: a phase II study of the european organization for research and treatment of cancer , 2000 .

[33]  G. Stathopoulos,et al.  Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Kris,et al.  Cisplatin versus carboplatin for patients with metastatic non-small-cell lung cancer--an old rivalry renewed. , 2007, Journal of the National Cancer Institute.

[35]  Y. Hayata.  16th World Conference on Lung Cancer. , 1999, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  G. Giaccone,et al.  Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955). , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Livingston.  Combination chemotherapy of bronchogenic carcinoma. I. Non-oat cell. , 1977, Cancer treatment reviews.

[38]  T. Boulikas.  Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. , 2004, Oncology reports.

[39]  M. Onofrj,et al.  Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy , 1997, Acta neurologica Scandinavica.

[40]  K. Meyer,et al.  Cisplatin nephrotoxicity. , 1994, Mineral and electrolyte metabolism.